^
    CANCER:

    T Acute Lymphoblastic Leukemia





    Show legend
    Group by Gene:
    Include preclinical:

    0
    DNA synthesis inhibitor
    nelarabine
    1
    Bcl2 inhibitor
    venetoclax
    2
    Topoisomerase II inhibitor, Alkylating agent, DNA inhibitor, DNA synthesis inhibitor
    cyclophosphamide + etoposide oral + nelarabine
    3
    Topoisomerase II inhibitor, Tubulin polymerization inhibitor, DNA synthesis inhibitor, Aspartate-ammonia ligase inhibitor, Asparagine depleter, DNA intercalator
    vincristine + daunorubicin + pegaspargase + nelarabine
    4
    CD7-targeted CAR-T immunotherapy
    CD7-targeted CAR-T immunotherapy
    5
    Bcl2 antagonist
    ABT-737
    6
    P21-activated kinase inhibitor
    FRAX597 + PF-3758309
    7
    PLK1 inhibitor, Bcl2 inhibitor
    venetoclax + NBL-001
    8
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    9
    JAK1 inhibitor, JAK2 inhibitor
    ruxolitinib
    10
    Glutaminase inhibitor
    CB-839
    11
    Electron transport complex I inhibitor
    IACS-010759
    12
    BET inhibitor
    JQ-1
    13
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib
    14
    PRPP amidotransferase inhibitor, DNA synthesis inhibitor
    mercaptopurine
    15
    CD38 inhibitor
    isatuximab-irfc
    16
    THF dehydrogenase inhibitor
    pralatrexate
    17
    Alkylating agent
    ACHM-025
    18
    CCR4 receptor antagonist
    mogamulizumab-kpkc
    19
    JAK3 inhibitor, JAK1 inhibitor, JAK2 inhibitor
    tofacitinib
    20
    Chemotherapy
    ADE
    21
    Tyrosine kinase inhibitor
    Tyrosine kinase inhibitor
    No biomarker
    SET-NUP214 fusion
    TP53 mutation
    MCL1 underexpression
    MYC underexpression
    CCND3 deletion
    JAK3 M511I
    NOTCH1 mutation
    BCL2L1 underexpression
    PRC2 mutation
    PCDHB15 overexpression
    NUP214-ABL1 rearrangement
    TCRB-LCK translocation
    RPL10 R98S
    NT5C2 R367Q
    CD38 expression
    DNMT3B overexpression
    AKR1C3 overexpression
    HGF-L
    JAK3 mutation
    FGFR1 rearrangement + Chr t(8;13)
    MEF2C overexpression
    PAK2 overexpression